President Donald Trump has expanded the "Most Favored Nations" drug pricing model to include more manufacturers. Nine additional companies have been brought on board, increasing the total number of participating companies to 26.

Further details about this development are available, including analysis from Dr. Oz on the potential impact of these deals on drug costs.

The expansion of the "Most Favored Nations" model is intended to lower drug pricing, although specific outcomes and effects are not specified in the initial information.